Clinical Trials Logo
  1. Home
  2. Relapsed Neuroblastoma
  3. NCT03406273

Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma

Relapsed Neuroblastoma Clinical Trial

Official title:
A Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma

Clinical Trial Summary

HITC001 is a single institution study to evaluate the efficacy of using a standardized protocol of surgery and radiation for patients with brain metastases in relapsed neuroblastoma.

Clinical Trial Description

This clinical trial aims to establish a standardized protocol consisting of surgery and radiation for patients with brain metastases in relapsed neuroblastoma. This will be an adjunct study to NMTRC009 onto which patients will be enrolled to for treatment with precision therapy. This study will follow the efficacy, safety, and CNS progression-free survival of surgery and radiation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03406273
Study type Interventional
Source Milton S. Hershey Medical Center
Contact
Status Withdrawn
Phase N/A
Start date May 2017
Completion date December 11, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04211675 - NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab Phase 1/Phase 2
Recruiting NCT05400603 - Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma Phase 1
Recruiting NCT05650749 - GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma Phase 1
Active, not recruiting NCT02282735 - Parental Decision-Making for Children With Relapsed Neuroblastoma
Withdrawn NCT03209869 - Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 Phase 1
Recruiting NCT04049864 - DNA Vaccination Against Neuroblastoma Early Phase 1
Suspended NCT01850888 - MIBG for Refractory Neuroblastoma and Pheochromocytoma N/A
Recruiting NCT04023331 - 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma Phase 1/Phase 2
Active, not recruiting NCT03635632 - C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Phase 1
Completed NCT01109238 - A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
No longer available NCT03649438 - 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma